Eledon Pharmaceuticals, Inc.
ELDN Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.21
KIRA · Stoqly’s AI analyst, in plain words
- Eledon Pharmaceuticals, Inc. lost $45.6M in fiscal 2025.
Market cap
$251M
P/E
—
Revenue
—
Net income
−$45.6M
Free cash flow
—
Operating margin
—
Eledon Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$45.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Eledon Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Eledon Pharmaceuticals, Inc.
- CIK
- 0001404281
Eledon Pharmaceuticals, Inc. · ELDN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$34.5M | −$88.0M | −$117M | −$36.2M | −$45.6M |
| Diluted EPS | −$2.33 | −$6.16 | −$4.73 | −$0.66 | −$0.52 |
| Cash | |||||
| Cash from operations | −$28.9M | −$28.4M | −$39.5M | −$47.3M | −$62.3M |
| Share count change | 921.1% | −3.6% | 72.3% | 97.2% | 68.6% |
| Debt and strength | |||||
| Cash and short-term investments | $84.8M | $56.4M | $51.1M | $140M | $133M |
| Shareholders' equity | $164M | $23.8M | −$48.5M | $62.4M | $81.1M |
| Current ratio | 20.1x | 9.2x | 14.4x | 12.4x | 7.4x |
| Returns and quality | |||||
| Return on equity | −19.5% | −93.7% | — | −518.4% | −63.6% |
| Return on tangible equity | −29.9% | −369.8% | — | −51.2% | −52.2% |
| Altman Z'' | 25.9 | −6.9 | −11.7 | — | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Eledon Pharmaceuticals, Inc. · ELDN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.21 a share, the company is worth $251M.
Source: SEC EDGAR XBRL filings (CIK 0001404281). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.